Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- AVO +20.9%, MTRX +9.6%, ORCL +8.5% (also announces strategic partnership with Amazon), CVGW +8.3% (also increases dividend), CGNT +7.9%, AZUL +6.7% (guidance), CDMO +2.2%
Other news:
- VRDN +11.7% (topline data from the THRIVE phase 3 clinical trial of VRDN-001, now known as veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in patients with active thyroid eye disease)
- CNTA +10.5% (interim data from an ongoing Phase 1 trial of its highly potent and selective orexin receptor 2 agonist, ORX750, in acutely sleep-deprived healthy volunteers)
- EVBN +6.8% (enters into merger agreement with NBT Bancorp)
- BOOT +6.2% (prelim Q2 comp growth)
- TXT +4.7% (subsidiary is one of other companies awarded $5.4 bln U.S. Air Force contract)
- INMD +4.7% (approved a share repurchase program of up to 7.68 million ordinary shares)
- INVH +4.4% (acquisitions update)
- SPRY +4.2% (submits sNDA to FDA)
- ARWR +3.4% (FDA has granted Breakthrough Therapy designation to investigational plozasiran)
- AGIO +3.2% (receives FDA orphan drug designation for treatment of myelodysplastic syndromes)
- KGS +3.1% (prices offering by selling shareholder of 6,086,957 shares of its common stock at $25.00 per share)
- CVAC +2.7% (to present first CVGBM glioblastoma cancer vaccine clinical data)
- VIR +2.3% (closes license agreement with Sanofi)
- DCBO +2.1% (appoints Alessio Artuffo as Chief Executive Officer and Board Member)
- ACHR +1.7% (CFO to take medical leave)
- CFLT +1.6% (acquires WarpStream)
- NRDS +1.5% (authorizes $50 mln for repurchases)
- RMBS +1.3% (releases AI workload accelerator)
- WOLF +1.3% (unveils carbide module solution)